Form 8-K - Current report:
SEC Accession No. 0001193125-20-134934
Filing Date
2020-05-06
Accepted
2020-05-06 16:24:53
Documents
18
Period of Report
2020-05-06
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d925911d8k.htm   iXBRL 8-K 45034
2 EX-1.1 d925911dex11.htm EX-1.1 134064
3 EX-4.3 d925911dex43.htm EX-4.3 99109
4 EX-5.1 d925911dex51.htm EX-5.1 18487
9 GRAPHIC g925911img001.jpg GRAPHIC 7816
10 GRAPHIC g925911img002.jpg GRAPHIC 6322
  Complete submission text file 0001193125-20-134934.txt   543325

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA amgn-20200506.xsd EX-101.SCH 4547
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE amgn-20200506_def.xml EX-101.DEF 13773
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE amgn-20200506_lab.xml EX-101.LAB 22821
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE amgn-20200506_pre.xml EX-101.PRE 14742
17 EXTRACTED XBRL INSTANCE DOCUMENT d925911d8k_htm.xml XML 6351
Mailing Address ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320
Business Address ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320 (805)447-1000
AMGEN INC (Filer) CIK: 0000318154 (see all company filings)

EIN.: 953540776 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37702 | Film No.: 20852974
SIC: 2836 Biological Products, (No Diagnostic Substances)